Safety and Efficacy of Tegileridine in Painless Gastrointestinal Endoscopy
This single-center, randomized, double-blind, active-controlled clinical trial aims to evaluate the safety and efficacy of tegileridine, a biased μ-opioid receptor agonist, in patients undergoing gastrointestinal endoscopy under sedation, compared with sufentanil. A total of 338 patients scheduled for gastrointestinal endoscopy under sedation were enrolled and randomly assigned in a 1:1 ratio to receive either tegileridine or sufentanil. The primary outcome is the incidence of respiratory depression. Secondary outcomes include the incidences of hypotension and postoperative nausea and vomiting, sedation success rate, supplemental propofol dose, procedure duration, recovery time, and patient satisfaction. This study will provide clinical evidence to support individualized and precision-based anesthesia strategies for gastrointestinal endoscopy.
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
详细说明
Background: Gastrointestinal endoscopy under sedation is a cornerstone of the diagnosis and treatment of digestive diseases, reducing patient discomfort and improving adherence. Conventional anesthesia with sufentanil and propofol is associated with significant adverse effects, including respiratory depression, gastrointestinal adverse reactions, postoperative nausea and vomiting (PONV), and hemodynamic fluctuations. Tegileridine mediates analgesia through preferential activation of G protein signaling at the μ-opioid receptor while reducing β-arrestin pathway activation, thereby lowering the risks of gastrointestinal adverse reactions and respiratory depression. To date, no clinical studies have investigated tegileridine for gastrointestinal endoscopy under sedation, and pharmacokinetic data and dose-adjustment guidelines for older adults remain unavailable.
Objectives: To systematically compare the safety and efficacy of tegileridine and sufentanil for gastrointestinal endoscopy under sedation, establish the suitability of tegileridine in this setting, and determine an appropriate dose for older patients, thereby supporting the development of individualized and precision-based anesthesia strategies.
Study Design: This is a single-center, randomized, double-blind, active-controlled trial. A total of 338 patients scheduled for gastrointestinal endoscopy under sedation will be enrolled and randomly assigned in a 1:1 ratio to the tegileridine group or the sufentanil group. Participants, staff involved in administering sedation, and outcome assessors will be blinded to treatment allocation. Only the nurses responsible for preparing the study medications will be unblinded.
Study Population: Eligible patients will be aged 18-75 years, have a body mass index (BMI) of 18.0-28.0 kg/m², a Mallampati airway classification of I or II, and an American Society of Anesthesiologists (ASA) physical status classification of I or II, have no contraindications to routine gastroscopy, and provide written informed consent. Exclusion criteria include severe cardiopulmonary disease, hepatic or renal failure, a history of opioid allergy, chronic opioid dependence, hypokalemia, a history of QT interval prolongation, pregnancy, and breastfeeding. Patients whose gastroscopy lasts longer than 30 minutes or who experience adverse events that cannot be resolved with treatment will be withdrawn from the study.
Interventions: Patients in the tegileridine group will receive intravenous tegileridine at 0.01 mg/kg, followed 3 minutes later by intravenous propofol at 1.5 mg/kg. Patients in the sufentanil group will receive intravenous sufentanil at 0.1 μg/kg, followed 3 minutes later by intravenous propofol at 1.5 mg/kg. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental propofol at 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.
Outcome Measures: The primary outcome is the incidence of respiratory depression, defined as a respiratory rate <8 breaths/min or peripheral oxygen saturation (SpO₂) <90%. Secondary outcomes include safety measures (hypotension, PONV, the need for airway interventions, and changes in vital signs at multiple time points), efficacy measures (sedation success rate, the number of supplemental propofol doses and total propofol dose, procedure duration, and recovery time), and patient satisfaction, assessed on a scale of 1-10.
Expected Results: Compared with the sufentanil group, the tegileridine group is expected to have a lower incidence of respiratory depression, a lower risk of PONV, and more stable vital signs while achieving adequate analgesia for gastrointestinal endoscopy under sedation. Tegileridine may therefore offer a safer anesthesia option for older patients and patients with obesity.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 第四阶段
联系人和位置
学习联系方式
学习联系方式
- 姓名:Fang Peng Gao, MS
- 电话号码:17760577442
- 邮箱:gao1664@163.com
学习地点
-
-
Hainan
-
Haikou、Hainan、中国、570311
- 招聘中
- The Second Affiliated Hospital of Hainan Medical University
-
接触:
- Fang Peng Gao, MS
- 电话号码:17760577442
- 邮箱:gao1664@163.com
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients aged 18-75 years scheduled for gastrointestinal endoscopy under sedation.
- Body mass index (BMI) of 18.0-28.0 kg/m².
- Mallampati airway classification of I or II.
- American Society of Anesthesiologists (ASA) physical status classification of I or II.
- No contraindications to routine gastroscopy.
- Written informed consent signed by the patient and their family member.
Exclusion Criteria:
- Severe cardiopulmonary disease.
- Hepatic or renal failure.
- History of opioid allergy.
- Chronic opioid dependence.
- Hypokalemia or a history of QT interval prolongation.
- Pregnancy or breastfeeding.
Withdrawal Criteria:
- Gastroscopy duration exceeding 30 minutes.
- Adverse events that cannot be resolved with treatment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Tegileridine Group
Tegileridine 0.01 mg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg. |
Tegileridine 0.01 mg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes. Tegileridine 0.01 mg/kg or sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes. |
|
有源比较器:Sufentanil Group
Sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg. |
Tegileridine 0.01 mg/kg or sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes. Sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes. |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Respiratory Depression
大体时间:Periprocedural, up to 2 hours
|
The primary outcome is the incidence of respiratory depression, defined as a respiratory rate <8 breaths/min or peripheral oxygen saturation (SpO₂) <90%. |
Periprocedural, up to 2 hours
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Hypotension
大体时间:Periprocedural, up to2 hours
|
Hypotension is defined as a decrease in systolic blood pressure (SBP) of more than 20% from baseline. The incidence of hypotension will be assessed during the periprocedural observation period and reported as the percentage of participants experiencing at least one episode of hypotension. |
Periprocedural, up to2 hours
|
|
Incidence of Postoperative Nausea and Vomiting (PONV)
大体时间:Periprocedural, up to 24 hours after the endoscopic procedure
|
The incidence of postoperative nausea and vomiting (PONV) will be assessed within 24 hours after completion of the endoscopic procedure. PONV is defined as the occurrence of at least one episode of nausea, vomiting, or both during the observation period. The outcome will be reported as the percentage of participants experiencing PONV. |
Periprocedural, up to 24 hours after the endoscopic procedure
|
|
Heart Rate
大体时间:Periprocedural, up to 2hours
|
Heart rate (beats/min) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room. |
Periprocedural, up to 2hours
|
|
Mean Arterial Pressure
大体时间:Periprocedural, up to 2 hours
|
Mean arterial pressure (MAP, mmHg) will be recorded at the following six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room. |
Periprocedural, up to 2 hours
|
|
Respiratory Rate
大体时间:Periprocedural, up to 2 hours
|
Respiratory rate (breaths/min) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room. |
Periprocedural, up to 2 hours
|
|
Peripheral Oxygen Saturation
大体时间:Periprocedural, up to 2 hours
|
Peripheral oxygen saturation (SpO₂, %) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room. |
Periprocedural, up to 2 hours
|
|
Percentage of Participants With Successful Sedation Based on Body Movement at Endoscope Insertion and Rescue Sedative Use
大体时间:Periprocedural, at endoscope insertion for body movement and throughout the endoscopic procedure for rescue sedative use. Sedation success is determined at procedure completion.
|
Percentage of participants who meet both criteria for successful sedation: no body movement at endoscope insertion and no use of any rescue sedative other than the study drug during the endoscopic procedure. |
Periprocedural, at endoscope insertion for body movement and throughout the endoscopic procedure for rescue sedative use. Sedation success is determined at procedure completion.
|
|
Number of Supplemental Propofol Doses and Total Propofol Dose
大体时间:Periprocedural, up to 2 hours
|
The number of supplemental propofol doses administered during the endoscopic procedure will be recorded for each participant. The total propofol dose (mg), including the initial dose and all supplemental doses, will also be calculated. Both outcomes will be assessed at the completion of the endoscopic procedure. |
Periprocedural, up to 2 hours
|
|
Procedure Duration
大体时间:During the endoscopic procedure
|
Procedure duration is defined as the time interval from endoscope insertion to endoscope withdrawal, measured in minutes. |
During the endoscopic procedure
|
|
Recovery Time
大体时间:Periprocedural,up to 2 hours
|
Recovery time is defined as the time interval from endoscope withdrawal to the time when the participant first meets the predefined discharge criteria for the post-anesthesia care unit (PACU), measured in minutes. |
Periprocedural,up to 2 hours
|
|
Patient Satisfaction
大体时间:Post-procedure assessment.
|
Post-procedure assessment.
|
|
|
Sedation Success Rate
大体时间:At the end of the procedure.
|
At the end of the procedure.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他研究编号
其他研究编号
- 2026-K68-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.